S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NYSE:GKOS

Glaukos - GKOS Stock Forecast, Price & News

$49.35
+1.14 (+2.36%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$47.80
$49.58
50-Day Range
$45.25
$52.48
52-Week Range
$33.33
$64.49
Volume
289,068 shs
Average Volume
473,904 shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.67

Glaukos MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
14.8% Upside
$56.67 Price Target
Short Interest
Bearish
10.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.38) to ($1.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

726th out of 1,005 stocks

Surgical & Medical Instruments Industry

71st out of 102 stocks


GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
2/22/2023
Today
3/26/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.67
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$44.00
Forecasted Upside/Downside
+14.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-99,190,000.00
Pretax Margin
-34.80%

Debt

Sales & Book Value

Annual Sales
$282.86 million
Book Value
$11.11 per share

Miscellaneous

Free Float
44,000,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
1.24

Key Executives

  • Thomas William Burns
    Chairman & Chief Executive Officer
  • Joseph E. GilliamJoseph E. Gilliam
    President & Chief Operating Officer
  • Alex Thurman
    Chief Financial Officer & Senior Vice President
  • Jay L. Katz
    Chief Medical Officer
  • Diane W. Biagianti
    Senior Vice President & General Counsel













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2023?

9 Wall Street research analysts have issued 12-month price targets for Glaukos' shares. Their GKOS share price forecasts range from $44.00 to $68.00. On average, they predict the company's stock price to reach $56.67 in the next year. This suggests a possible upside of 14.8% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2023?

Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 13.0% and is now trading at $49.35.
View the best growth stocks for 2023 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,720,000 shares, an increase of 5.6% from the February 13th total of 4,470,000 shares. Based on an average trading volume of 398,600 shares, the days-to-cover ratio is presently 11.8 days. Currently, 10.3% of the company's stock are sold short.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, February, 22nd. The medical instruments supplier reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03. The medical instruments supplier earned $71.23 million during the quarter, compared to analyst estimates of $67.71 million. Glaukos had a negative net margin of 35.07% and a negative trailing twelve-month return on equity of 18.51%.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $290.00 million-$295.00 million, compared to the consensus revenue estimate of $304.65 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (3.99%), Braidwell LP (3.48%), Fred Alger Management LLC (2.78%), Point72 Asset Management L.P. (2.42%), Geode Capital Management LLC (1.74%) and Morgan Stanley (1.70%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $49.35.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.36 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 3/26/2023 by MarketBeat.com Staff